Our findings regarding PI3K/AKT/mTOR pathway inhibitors parallel work with rapamycin, which has shown promise in targeting aging-related and metabolic aspects of AD pathology (Spilman et al., 2010; Harrison et al., 2009). This evidence concerns the gene MTOR and Alzheimer disease.